Coronavirus Patients Taken Off Ventilators and Out of ICU After Receiving Experimental Drug Leronlim

[Elderberry]

Gateway Pundit by Jim Hoft March 28, 2020

Two patients in New York City were taken off ventilators taken out of intensive care after they received the experimental drug leronlimab.

At least two of seven patients on leronlimad saw significant improvement.

This follows the news on Friday that the renowned French epidemiologist Dr. Didier Raoult was able to repeat his findings from a previous study on the use of hdroxychloroquine on coronavirus patients.

The New York Post reported:

    Two coronavirus patients in New York City are off ventilators and out of intensive care after they received an experimental drug to treat HIV and breast cancer.

More: https://www.thegatewaypundit.com/2020/03/coronavirus-patients-taken-off-ventilators-and-out-of-icu-after-receiving-experimental-drug-leronlimab/

[Elderberry]

Leronlimab Used in Seven Patients with Severe COVID-19 Demonstrated Promise with Two Intubated Patients in ICU, Removed from ICU and Extubated with Reduced Pulmonary Inflammation

Cytodyn 3/27/2020

https://www.cytodyn.com/newsroom/press-releases/detail/399/leronlimab-used-in-seven-patients-with-severe-covid-19


Download as PDF

IncellDx’s evaluation of test results from the first four patients suggests immunological benefit within three days following treatment with leronlimab on all four patients and lower level of cytokine storm, especially IL-6 and TNF-α, which were reduced significantly

VANCOUVER, Washington, March 27, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the three-day results post-leronlimab treatment of the first four patients under an Emergency Investigational New Drug (EIND) granted by the U.S. Food and Drug Administration (FDA).  A total of seven patients have been enrolled thus far under EIND in the same leading medical center in the New York City area.

The treatment with leronlimab is targeted as a therapy for patients who experience respiratory complications as a result of contracting SARS-CoV-2 causing the Coronavirus Disease 2019 (COVID-19).  Leronlimab is believed to provide therapeutic benefit by enhancing the immune response while mitigating the “cytokine storm” that leads to morbidity and mortality in these patients.

Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostic partner and advisor to CytoDyn, said, “IncellDx has developed specific companion diagnostic tests to determine the efficacy and dosing of leronlimab in these severe cases of COVID-19. We found that patients with severe COVID-19 disease are in the midst of immunologic chaos which includes the cytokine storm. Our companion diagnostics showed that after three days of therapy, the immune profile in these patients approached normal levels and the levels of cytokines involved in the cytokine storm were much improved.”

More at link.

[catfish1957]

Leronlimab Used in Seven Patients with Severe COVID-19 Demonstrated Promise with Two Intubated Patients in ICU, Removed from ICU and Extubated with Reduced Pulmonary Inflammation

I haven't commented much on the experimental cures thus far, but I do hope someone is keeping a tally of fatalites caused by FDA regulatory red tape.

[jafo2010]

And this med cost what, $5,000 a pill I'll bet!!!

[Cyber Liberty]

For the Love of God, please don't let Trump mention this, or patients in Michigan and Nevada are going to die.  They are on record as declaring themselves on the side of cancer, were Trump to announce a cure.

[jafo2010]

People in Nevada are going to die unnecessarily because they have an idiot for governor.  His restricting the use of Hydroxychloroquine is criminal, and people will die because of his ignorance.